Literature DB >> 11681761

Integrated treatment of comorbid depression and substance use disorders.

D A Charney1, A M Paraherakis, K J Gill.   

Abstract

OBJECTIVE: The goals of this 6-month prospective study were to evaluate the effect of a current diagnosis of depression on the course and outcome of addiction treatment and to determine whether patients with depression received or required additional treatment compared with those without depression.
METHOD: On entering addiction treatment, 75 men and 45 women with substance use disorders were assessed by clinical and semistructured interviews, Global Assessment Scale, Hamilton Rating Scale for Depression, Beck Depression Inventory, and revised 90-item Symptom Checklist.
RESULTS: Forty-three patients (35.8%) met DSM-IV criteria for a current depressive disorder at intake into addiction treatment. The depressed patients had significantly (p < .0001) higher levels of psychopathology at intake. However, contrary to previous studies, they fared as well as the nondepressed patients in terms of all addiction outcome measures and all indicators of psychiatric status at 6 months. During the 6-month follow-up period, the depressed patients received more treatment than the nondepressed patients. Specifically, they had more psychiatric appointments, and they were more likely to require inpatient detoxification and to be prescribed new antidepressant medication regimens.
CONCLUSION: Depression comorbidity may not have had a negative impact on the course and outcome of addiction treatment because the dual disorder was identified at the initial assessment, and integrated psychiatric care was available. It may be that additional treatment compensated for greater psychopathology among dual-disorder patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11681761     DOI: 10.4088/jcp.v62n0902

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

1.  Treating depression and substance use: a randomized controlled trial.

Authors:  Sarah B Hunter; Katherine E Watkins; Kimberly A Hepner; Susan M Paddock; Brett A Ewing; Karen C Osilla; Suzanne Perry
Journal:  J Subst Abuse Treat       Date:  2012-02-01

Review 2.  Behavioral therapies for co-occurring substance use and mood disorders.

Authors:  Kathleen M Carroll
Journal:  Biol Psychiatry       Date:  2004-11-15       Impact factor: 13.382

Review 3.  Co-occurring disorders in substance abuse treatment: issues and prospects.

Authors:  Patrick M Flynn; Barry S Brown
Journal:  J Subst Abuse Treat       Date:  2007-06-15

4.  Psychiatric Symptom Improvement in Women Following Group Substance Abuse Treatment: Results from the Women's Recovery Group Study.

Authors:  R Kathryn McHugh; Shelly F Greenfield
Journal:  J Cogn Psychother       Date:  2010-04-01

5.  Screening for Mood Disorder in Pregnant Substance-dependent Patients.

Authors:  Margaret S Chisolm; Michelle Tuten; Eric C Strain; Hendrée E Jones
Journal:  Addict Disord Their Treat       Date:  2009-06-01

6.  Performance of the CJDATS Co-Occurring Disorders Screening Instruments (CODSIs) among minority offenders.

Authors:  Alexandra Duncan; Stanley Sacks; Gerald Melnick; Charles M Cleland; Frank S Pearson; Carrie Coen
Journal:  Behav Sci Law       Date:  2008

7.  Psychiatric discharge process.

Authors:  Hamzah M Alghzawi
Journal:  ISRN Psychiatry       Date:  2012-09-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.